Next Phase Newsletter

A venture capital firm based in Hong Kong manages a USD fund that focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in the U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. VI can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture fund founded in 2018 focuses on early-stage diagnostics, life science research tools, and biotech-related companies. The firm’s initial investment size is $500K-$1M. The firm prefers to act as the co-investor with other types of investors such as strategic partners. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early-stage diagnostics, life science research tools, and biotech-related companies. The firm will invest in a limited number of therapeutic opportunities. The firm also has interests in other technology fields. The firm is opportunistic in terms of subsectors and indications. The firm will consider investing in companies that have strong intellectual property protection and provide barriers to competitive entry. The firm also seeks companies with potential large addressable markets, which typically have the potential to generate at least $100M of annual revenues.

The firm seeks a reliable and experienced management team that can bring the concept to market. The firm may take a board seat in applicable cases. The firm aims to back fundraising CEOs that are driven to deliver exceptional investment returns to both investors and management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices across Europe is investing from a EUR 120 million fund raised in 2019. The firm makes equity investments in early-to-late stage therapeutics, diagnostics, and medical devices companies. The firm can generally allocate between €2M to €10M. The firm only invests in companies that are based in Central and Western Europe. The firm is actively seeking new investment opportunities.

The firm is very opportunistic in the life sciences space. The firm focuses on therapeutics, diagnostics, and medical devices companies and is also interested in digital health. The firm targets therapeutic products in clinical trials or which are ready to enter Phase I, and medical devices which are CE Mark ready. The firm is very opportunistic in terms of subsectors and indications. However, the firm does not invest in cosmetics and dental devices. The firm strongly prefers companies developing products that address a highly unmet medical need. In digital health, the firm prefers to invest in products that have or are pursuing regulatory approval to monitor or treat a condition in which there is an unmet medical need. Generally these products will include both a hardware and a software component. The firm is not interested in consumer or lifestyle health products.

The firm plays the role of lead or co-lead investor in the large majority of its financing rounds. The firm requires a board seat in its portfolio companies. The firm seeks a company with a strong and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large US health system established an investment unit designed to achieve venture class returns through direct investments in innovative healthcare companies. In 2019 the firm closed a second $150 million venture and growth equity fund.  Typical equity allocations range from $8-15 million over the life of a company. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission to improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system. The firm is open to investing as a lead or co-investing along a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the USA invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies. The firm will generally lead investments and invests globally with no geographic restrictions.

The firm is agnostic across life science sectors, including therapeutics, devices and tools, but will not consider healthcare IT or digital health technologies. The firm focuses on discovery, early stage preclinical and clinical-stage opportunities, though may be open to commercial-stage or adjacent discovery/ development technologies.

The firm is seeking companies with founders who have a clear vision and desire to build a durable business.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large biologics company headquartered in China with additional operations in USA and Asia, focuses on the development and commercialization of antibody-based therapeutics using advanced technologies. The company has a special focus on biosimilars and biobetters (mAbs and recombinant proteins) for malignant tumors (including solid tumor, lymphoma, etc.) and auto-immune diseases. Currently, the company’s pipeline covers over 8 biosimilars and 10 novel antibody products in pre-clinical and clinical development.

In addition to seeking out-licensing opportunities and strategic partnerships, the company is also seeking to in-license novel antibody product candidates in oncology that has synergies with the company’s current portfolio.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm established in early 2019 by a large network of hospitals, clinics, and home care services in the USA does direct, strategic investment in early-stage companies (with approximately half of this allocation dedicated to follow-on investments). The firm’s initial investments are usually in the range of $1-3M. The firm is geography agnostic and will consider all technologies across the globe.

The firm’s investments focuses on these 4 verticals: digital health, medical devices, healthcare technology systems, and healthcare services. The firm will not invest in biopharmaceuticals or in vitro diagnostics, though they may consider life science tools. In terms of medical devices, the firm prefers to invest in products who have achieved FDA approval, though the firm may consider and is open to speaking with earlier stage companies with strong fit. The firm expects technologies to have a strong alignment with the hospital network, and these technologies need to be useable and easily integrated with the health system. Practically, the firm expects to have a contract (or direct line of sight to a contract) at the time of investment. Some areas of particular interest include mental and behavioral health, postpartum care, interoperability among devices and health records, cognitive support for millennials, use of voice to diagnose and monitor health conditions, etc. Overall, the firm will take high interest in technologies that help deliver care outside of the hospital.

While the firm has no specific team requirements, the firm does like to see entrepreneurs and management teams with a strong tie to the product or market. To date, the firm has only done follow-on investments as part of a syndicate, but will be open to acting as lead investor in future opportunities, most likely starting from 2020 and beyond.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.